<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124430">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01974973</url>
  </required_header>
  <id_info>
    <org_study_id>NGBSI-02</org_study_id>
    <nct_id>NCT01974973</nct_id>
  </id_info>
  <brief_title>Stem Cell Therapy in Autism Spectrum Disorders</brief_title>
  <official_title>Open Label Study of Autologous Bone Marrow Mononuclear Cells in Autism Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogen Brain and Spine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogen Brain and Spine Institute</source>
  <oversight_info>
    <authority>India: Indian Council of Medical Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to study the effect of stem cell therapy on common symptoms in
      patients with autism spectrum disorders
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in the scales for Autism spectrum disorders</measure>
    <time_frame>Six months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positron Emission Tomography- computed tomography to study change in brain metabolism</measure>
    <time_frame>six months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Autism Spectrum Disorders</condition>
  <arm_group>
    <arm_group_label>Stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>autologous bone marrow mononuclear cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell transplantation</intervention_name>
    <arm_group_label>Stem cell</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell transplantation in patients with autism</intervention_name>
    <arm_group_label>Stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed cases of any type of autism spectrum disorders

          -  age above 6 months

        Exclusion Criteria:

          -  presence of acute infections such as Human immunodeficiency virus/Hepatitis B
             Virus/Hepatitis C Virus

          -  malignancies

          -  bleeding tendencies

          -  pneumonia

          -  renal failure

          -  severe liver dysfunction

          -  severe anemia [Hemoglobin &lt; 8]

          -  any bone marrow disorder

          -  space occupying lesion in brain

          -  other acute medical conditions such as respiratory infection and pyrexia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alok K Sharma, M.S, M.Ch</last_name>
    <phone>91-22-25281610</phone>
    <email>alok276@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neurogen brain and spine institute</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400071</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok K Sharma, M.S, M.Ch.</last_name>
      <phone>91-22-25281610</phone>
      <email>alok276@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Geffner LF, Santacruz P, Izurieta M, Flor L, Maldonado B, Auad AH, Montenegro X, Gonzalez R, Silva F. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies. Cell Transplant. 2008;17(12):1277-93.</citation>
    <PMID>19364066</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 5, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autism spectrum disorders</keyword>
  <keyword>stem cells</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
